Get started
Work

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

Year: 2019
Type: conference-abstract
DOI: 10.1016/j.jtho.2019.08.426
Authors: C. Langer, S. Gadgeel, H. Borghaei, A. Patnaik, S. Powell, R. Gentzler, J.C. Yang, M. Gubens, L. Sequist, M. Awad, R. Cristescu, D. Aurora-Garg, A. Albright, A. Loboda, J. Kobie, J. Lunceford, M. Ayers, G. Lubiniecki, B. Piperdi, M.C. Pietanza, V. Papadimitrakopoulou
Institutions: Abramson Cancer Center, University of Pennsylvania, University of Michigan, The Barbara Ann Karmanos Cancer Institute, Fox Chase Cancer Center, South Texas Accelerated Research Therapeutics, Sanford Health, University of Virginia, National Taiwan University Hospital, University of California, San Francisco, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2981875618
Cites:
Cited by: 66
Related to: 10